* Cogent Biosciences Inc COGT.OQ COGT.O is expected
to show no
change in quarterly revenue when it reports results on August 6
(estimated) for the period ending June 30 2024
*
* LSEG's mean analyst estimate for Cogent Biosciences Inc
is for
a loss of 56 cents per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 9 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Cogent
Biosciences Inc is $17.00, above its last closing price
of $9.36.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT ESTIMATE MET, SE %
E® MISSED
Mar. 31 2024 -0.52 -0.52 -0.62 Missed -20.1
Dec. 31 2024 -0.62 -0.56 -0.63 Missed -11.8
Sep. 30 2023 -0.50 -0.50 -0.64 Missed -27.8
Jun. 30 2023 -0.55 -0.54 -0.59 Missed -8.3
Mar. -0.58 -0.57 -0.54 Beat 5.4
31 2023
Dec. 31 2022 -0.54 -0.52 -0.56 Missed -8.3
Sep. 30 2022 -0.53 -0.51 -0.50 Beat 2.6
Jun. 30 2022 -0.68 -0.65 -0.71 Missed -9
This summary was machine generated August 2 at 16:13 GMT. All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)